遺伝子検査市場：製品タイプ、技術、用途、流通チャネル、エンドユーザー別- 世界予測2024-2030年

遺伝子検査市場規模は2023年に118億9,000万米ドルと推計され、2024年には135億5,000万米ドルに達し、CAGR 14.01％で2030年には297億9,000万米ドルに達すると予測されます。

遺伝子検査は、個人のDNAを解析し、遺伝形質、疾患素因、治療反応に関連する特定の遺伝子、染色体、タンパク質を特定するための多様な製品とサービスから構成されます。臨床診断、医薬品研究開発、バイオテクノロジー革新、法医学、ニュートリゲノミクス、消費者直販サービスなど、さまざまな分野がこの市場の重要な事業分野です。近年の遺伝子検査市場の著しい成長には、いくつかの要因が寄与しています。次世代シーケンシング（NGS）などのDNAシーケンシング技術の進歩、遺伝子検査による早期診断の利点に関する認知度の向上、遺伝性疾患の有病率の増加、人口の高齢化、個別化医療に対する需要の高まり、消費者向け遺伝子検査サービスの利用拡大、有利な償還シナリオと相まって支持的な政府政策などです。遺伝子検査市場における新たな成長機会としては、人工知能（AI）、ビッグデータ分析、遠隔医療プラットフォームなど他の最先端技術との統合、アジア太平洋などの高成長市場への参入、ゲノム研究イニシアチブを強化するための官民パートナーシップの促進、個人の遺伝子プロファイルに合わせた精密医療プログラムの適用、血液サンプル中の循環腫瘍DNA（ctDNA）を介した早期がん検出のためのリキッドバイオプシー技術の利用などが挙げられます。とはいえ、プライバシーの問題や遺伝情報の悪用に関する倫理的な懸念、遺伝子検査の重要性に関する一般市民の認識不足、特定の人口層に対する高度な検査の高額な費用による経済的な制約、国によって一貫性のないガイドラインや規制、ヘルスケア専門家や患者による誤った解釈につながる誤った結果に対する懸念、認定遺伝カウンセラーなどの分野における労働力不足など、いくつかの限界や課題によって成長の可能性は妨げられています。

遺伝子検査市場におけるイノベーションと研究開発は、CRISPR-Cas9のような新規遺伝子編集技術の開発、ハイスループットシーケンスプラットフォームによって生成される膨大なゲノムデータのより良い解釈のためのバイオインフォマティクスツールの強化、無細胞胎児DNA（cffDNA）を用いた非侵襲的出生前検査（NIPT）における新たなアプリケーションの探求に向けられるべきである；薬理ゲノミクス・アプローチによって標的となりうる疾患状態に対するユニークなバイオマーカーを発見すること、様々な環境要因に対する個人の反応を評価するための環境ゲノミクスなどの分野に進出すること。

製品：効率的なデータ管理と解析のためのソフトウェアとサービスの普及

遺伝子検査業界における消耗品および機器には、試薬、アッセイキット、実験器具、およびサンプルの収集、処理、分析に必要な機器などの製品が含まれます。この分野は、様々な用途において正確で信頼性の高い検査を実施するために不可欠です。診断研究所では、疾患の正確な診断のために、試薬やアッセイキットを含む高品質の消耗品が必要とされます。また、研究機関では、分子レベルでの遺伝学的研究を行うため、シークエンサーやPCR装置などの高度な機器が必要とされます。一方、ソフトウェアとサービスには、データの保存、管理、解析のためのバイオインフォマティクスツールや、遺伝カウンセリングやコンサルティングサービスが含まれます。ソフトウェアとサービスは、複雑なゲノムデータの効率的な取り扱いに対するニーズの高まりに応えるデータ管理と解析ソリューションに重点を置いています。

検査の種類：特定の疾患を診断するための診断検査に重点を置いています。

保因者検査は、遺伝性疾患の原因となる遺伝子変異のコピーを1つ持つ個人を、他の保因者と組ませた場合に、その子孫を同定するために実施されます。特に特定の遺伝的疾患の家族歴がある場合、子供を持つ予定のカップルに勧められることが多いです。一方、診断検査は、個人が病気の症状を発症した後や、特定の診断を確認または除外する必要がある場合に実施されます。新生児スクリーニング検査は、新生児の生命を脅かす可能性のある感染症をできるだけ早期に発見し、迅速な医療介入を開始するのに役立ちます。この検査では通常、出生直後に採血が行われ、聴力検査や先天性心疾患のパルスオキシメトリー検査が行われることもあります。ファーマコゲノミクス研究は、個人の遺伝的体質が薬物反応にどのように影響するかを明らかにするものです。これらの違いを理解することで、ヘルスケア専門家は薬物療法の選択と投与量を最適化し、治療成績を向上させることができます。着床前診断とは、子宮着床前に先天性異常を特定するために、体外受精（IVF）で得られた胚に対して行われるものです。着床前検査には主に、特定の遺伝性疾患をスクリーニングする着床前遺伝子診断（PGD）と、胚の染色体構成を評価する着床前遺伝子スクリーニング（PGS）の2種類があります。出生前検査は、妊娠中の潜在的な健康問題の発見に役立ち、診断検査（例：羊水穿刺）及びスクリーニング検査（例：非侵襲的出生前検査（NIPT））が含まれます。無症候性及び予測検査は、無症候性で、後に特定の疾患を発症するリスクが高い可能性のある人の遺伝子変異を同定するものです。この検査情報により、個人は健康管理戦略について十分な情報に基づいた決定を下したり、疾病リスクを低減するための予防措置を講じたりすることができます。

技術：正確な遺伝子同定と疾患診断のためのDNA配列決定へのシフトの増加

細胞遺伝学は、染色体異常と遺伝性疾患におけるその役割の研究です。細胞遺伝学技術では、染色体の構造と数を分析し、疾患発症に関与する可能性のある異常を特定します。一般的な細胞遺伝学的検査には、核型分析や蛍光in situハイブリダイゼーション（FISH）などがあります。DNA配列決定技術は、DNA分子内のヌクレオチドの正確な順序を解読し、遺伝子を同定し、その機能を決定します。この技術は、遺伝性疾患の診断、がん細胞内の遺伝子変異の検出、個別化医療アプローチの指針として、ニーズが高いです。遺伝子発現プロファイリングは、病気の発症や進行における遺伝子の役割を理解するために、何千もの遺伝子の活性レベルを同時に測定します。遺伝子発現プロファイリング技術は、新規治療標的の同定、治療反応の理解、個別化治療決定の指針として有用です。マイクロアレイとRNAシーケンス（RNA-seq）は、遺伝子発現プロファイリングによく用いられる技術です。マイクロアレイは、遺伝子発現を解析したり、一塩基多型（SNP）などの遺伝的変異を検出したりする高スループット技術プラットフォームです。ゲノムレベルでの遺伝子機能の研究や、潜在的な疾患関連バイオマーカーのスクリーニングなど、ニーズに応じて選択されます。PCRは、特定のDNA配列を増幅し定量するための分子生物学的手法として広く利用されています。PCRは遺伝子検査、病原体の検出、法医学的分析など様々な応用があります。PCRは、最小限のサンプルで迅速かつ正確に結果を得ることができるため、ニーズが高いです。

アプリケーションがんの初期徴候を検出するための遺伝子検査の採用増加

自己免疫疾患は、免疫システムの機能不全から生じ、身体の細胞や組織を攻撃します。遺伝子検査は、これらの疾患の遺伝的素因を特定し、早期発見と的を絞った治療計画を可能にする上で極めて重要です。個人の遺伝的体質を包括的に理解することは、がんの初期徴候の発見や家族性リスクの特定に役立ち、個人に合わせた予防戦略や標的治療を可能にします。心臓病、糖尿病、肥満は、環境要因と遺伝が複雑に絡み合っています。遺伝子検査は、これらの疾患に対する個人の感受性を判定し、リスクを軽減するためのオーダーメイドのライフスタイル介入や投薬計画の立案に役立ちます。嚢胞性線維症、筋ジストロフィー、サラセミアは特定の遺伝子の変異によって引き起こされます。遺伝子検査は、遺伝性疾患の正確な診断を可能にし、子供を持つ予定のリスクのあるカップルを特定するためのキャリアスクリーニングを可能にします。アルツハイマー病、パーキンソン病、ハンチントン病などの神経変性疾患は、遺伝的な関連が強い場合があります。遺伝子検査は、これらの疾患の素因を明らかにし、疾患の進行を遅らせるための予防措置や早期介入を可能にします。

販売チャネル：オンラインプラットフォームでの遺伝子検査製品の展開

オフラインの流通には、病院、クリニック、診断研究所などの伝統的な実店舗が含まれ、ヘルスケア専門家との対面による個別指導を求める個人を対象としています。オフライン販売の主な利点は、医療専門家との直接相談、安全なサンプル採取プロトコル、包括的な保険適用オプション、必要な場合のフォローアップケアへの即時アクセスなどです。オンライン販売は遺伝子検査市場において急成長しているセグメントであり、自宅からの便利なアクセスを求めるハイテクに精通した人々にアピールしています。主要なDTC（Direct-to-Consumer）ブランドは、主にウェブサイトやeコマース・プラットフォームを通じて家系や健康関連の検査を提供しています。オンラインによる遺伝子検査の利点は、使いやすさ（サンプル採取キットはユーザーに直接郵送される）、迅速な納期、費用対効果、幅広い検査へのアクセスなどです。しかし、オフラインのチャネルで利用できる個別化された医療サポートには欠けるかもしれないです。最終的には、オフラインとオンライン配布のどちらを選択するかは、個人の嗜好やニーズによって決まる。

エンドユーザー：病気の診断と治療計画のために、病院や診療所で遺伝子検査ソリューションが広く使用されています。

遺伝子検査では、診断ラボの専門的なサービスと豊富な検査項目が重要な役割を果たしています。家系、健康リスク、個人的特徴に関する洞察を提供するDTC（Direct-to-Consumer）検査の需要の高まりにより、ホームセッティングの遺伝子検査が人気を集めています。病院や診療所は、病気の診断や治療計画のために、患者のケア経路に遺伝子検査サービスを統合しているため、エンドユーザーにとってもう一つの重要な部分を形成しています。病院は、患者の遺伝的体質に基づいて薬物選択を調整するために、ファーマコゲノミクス検査を取り入れ始めています。

地域の洞察

南北アメリカの高度な医療インフラと研究開発に対する政府の強力な支援が、遺伝子検査市場の繁栄につながっています。しかし、製造業者は食品医薬品局（FDA）などの機関が定めた厳格なガイドラインを遵守しなければならないため、規制面での課題は依然として残っています。欧州は、加盟国によって規制が異なり、多様な様相を呈しています。英国のブレグジットは、その規制の枠組みに不確実性をもたらしています。メーカーやプロバイダーは、各国固有の要件に合わせて戦略を立てなければならないです。中東・アフリカは、人口の増加と慢性疾患の増加により、医療提供者にとって潜在的な可能性を秘めています。しかし、ヘルスケアインフラが限られており、遺伝子検査サービスに対する認知度が低いため、これらの市場への参入には課題があります。APAC地域は、中国、日本、インドにおいて大きな成長機会を提供しており、これらの地域は患者数が多く、正確な診断と遺伝性疾患の積極的な管理が必要とされています。先進諸国と同様の規制上のハードルはあるもの、現地のニーズに対応したイノベーションの余地があります。遺伝子検査は、先進国では個別化医療と予防ヘルスケアに不可欠なものとなりつつあるが、複雑な規制をうまく乗り切ることが重要です。新興諸国では、市場拡大の可能性があるため、現地とのパートナーシップ、教育イニシアティブ、インフラ整備に投資しています。最近のニュースでは、遺伝子検査市場における製品提供の向上を目指したコラボレーションが注目されています。世界の遺伝子検査動向は、地域ごとの動向を常に把握し、それに合わせて戦略を適応させることで、最終的に世界の公衆衛生の成果に大きく貢献します。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは遺伝子検査市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、遺伝子検査市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.遺伝子検査市場の市場規模および予測は？

2.遺伝子検査市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.遺伝子検査市場の技術動向と規制枠組みは？

4.遺伝子検査市場における主要ベンダーの市場シェアは？

5.遺伝子検査市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遺伝性疾患および腫瘍性疾患の有病率と精密医療の必要性
    • 遺伝子検査に対する政府の取り組みと自己検査キットの普及
  • 抑制要因
    • 遺伝子検査の偽陽性と偽陰性に関する懸念
  • 機会
    • 遺伝子検査テクノロジーの継続的な調査と新開発
    • 遠隔医療とデジタルヘルスプラットフォームによる遺伝子検査の出現
  • 課題
    • 遺伝子検査に対する物流上の障壁とプライバシーの懸念
• 市場セグメンテーション分析
  • 製品：効率的なデータ管理と分析のためのソフトウェアとサービスの普及
  • 検査の種類：特定の病気の診断を行うための診断検査に重点を置く
  • テクノロジー：正確な遺伝子特定と疾患診断のためのDNAシーケンシングへの移行が増加
  • 応用：がんの早期兆候を検出するために遺伝子検査の採用が増加
  • 流通チャネル：遺伝子検査製品のオンラインプラットフォームへの展開
  • エンドユーザー：病院や診療所で病気の診断や治療計画のために遺伝子検査ソリューションを広く使用
• 市場動向分析
  • 技術の進歩と確立された製薬会社の存在が、南北アメリカにおける遺伝子検査市場の成長を促進しています。
  • 慢性疾患の増加とヘルスケアインフラの拡大は、APAC地域における遺伝子検査をサポートします。
  • 政府の取り組みと個別化医療の需要増加により、EMEA地域で遺伝子検査市場の成長が拡大しています。
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 遺伝子検査市場：製品別

• 消耗品と装備
• ソフトウェアとサービス

第7章 遺伝子検査市場テストタイプ別

• キャリアテスト
• 診断検査
• 新生児スクリーニング
• 薬理ゲノム学
• 着床前検査
• 出生前検査
• 発症前および予測検査

第8章 遺伝子検査市場：技術別

• 細胞遺伝学
• DNA配列解析
• 遺伝子発現プロファイリング
• マイクロアレイ
• PCR

第9章 遺伝子検査市場：用途別

• 自己免疫疾患
• がん
• 慢性疾患
• 遺伝性疾患
• 神経変性疾患

第10章 遺伝子検査市場：流通チャネル別

• オフライン
• オンライン

第11章 遺伝子検査市場：エンドユーザー別

• 診断検査室
• ホーム設定
• 病院・クリニック

第12章 南北アメリカの遺伝子検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の遺伝子検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの遺伝子検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • DNA会社アサ・レンが800万米ドルを調達、さらに概要も発表
  • Devyser、遺伝性がんに対する2つの新しい遺伝子検査ソリューションを発表
  • ブループリント・ジェネティクスは、家族計画や将来の健康に関する実用的な洞察を提供する新しいスクリーニング検査ファミリーを導入しました。
  • KindbodyがKindlabsの立ち上げにより遺伝子検査を社内に導入
  • 遺伝子検査デルブ社がベンチャーキャピタルから3,500万米ドルの資金を獲得
  • FBIが米国国家DNAインデックスシステム（NDIS）向けにQIAGENのNGSベースのForenSeq MainstAYワークフローを承認
  • Sema4、遺伝子検査企業GeneDxを6億2,300万米ドルで買収へ
  • スクライブとサノフィ、遺伝子治療開発契約を拡大
  • healthOmeがKailos Geneticsを買収
  • MapMyGenome、パーソナライズされたスキンケアとヘアケアのためのインド初のDNA検査を開始
  • CENTOGENE、武田との戦略的提携を拡大し、リソソーム蓄積疾患患者に遺伝子検査へのアクセスを継続的に提供
  • PathogenDxは特許取得済みのマルチプレックス分子検査技術の範囲を拡大し、臨床、食品、農業分野に導入します。
  • アジレント、がん調査向け高性能NGSターゲットエンリッチメントワークフローの開発会社Avida Biomedの買収を発表
  • InvitaeがEpicとの提携を発表し、遺伝子検査の効率化を図る
  • インドネシアで包括的なDNAテスト DNATEST.IDがグランドローンチ
  • MyHeritageがDNA一致間の家族関係をより正確に予測するcM Explainerをリリース

第16章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. GENETIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. GENETIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GENETIC TESTING MARKET DYNAMICS
• FIGURE 7. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. AMERICAS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. AMERICAS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. UNITED STATES GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 22. UNITED STATES GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 27. GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 28. GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENETIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 105. CANADA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 106. CANADA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 107. CANADA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 108. CANADA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 109. CANADA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 110. CANADA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 111. CANADA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. CANADA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. CANADA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 114. CANADA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 115. CANADA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 116. CANADA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 169. CHINA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 170. CHINA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 171. CHINA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 172. CHINA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 173. CHINA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 174. CHINA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 175. CHINA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. CHINA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. CHINA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 178. CHINA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 179. CHINA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 180. CHINA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 181. INDIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 182. INDIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 183. INDIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 184. INDIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 185. INDIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 186. INDIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 187. INDIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. INDIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. INDIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 190. INDIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 191. INDIA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. INDIA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 203. INDONESIA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 204. INDONESIA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 215. JAPAN GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. JAPAN GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 227. MALAYSIA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 228. MALAYSIA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 239. PHILIPPINES GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. PHILIPPINES GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 251. SINGAPORE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. SINGAPORE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 263. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. SOUTH KOREA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 275. TAIWAN GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. TAIWAN GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 287. THAILAND GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. THAILAND GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 298. VIETNAM GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 299. VIETNAM GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 300. VIETNAM GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 313. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 314. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 319. DENMARK GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 320. DENMARK GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 321. DENMARK GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 322. DENMARK GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 323. DENMARK GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 324. DENMARK GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 325. DENMARK GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 326. DENMARK GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 331. EGYPT GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 332. EGYPT GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 333. EGYPT GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 334. EGYPT GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 335. EGYPT GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 336. EGYPT GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 337. EGYPT GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 338. EGYPT GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 339. FINLAND GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 340. FINLAND GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 341. FINLAND GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 342. FINLAND GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 343. FINLAND GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 344. FINLAND GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 345. FINLAND GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 346. FINLAND GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 347. FINLAND GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 348. FINLAND GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 349. FINLAND GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 350. FINLAND GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 351. FRANCE GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 352. FRANCE GENETIC TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 353. FRANCE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 354. FRANCE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 355. FRANCE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 356. FRANCE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 357. FRANCE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 358. FRANCE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 359. FRANCE GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 360. FRANCE GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 361. FRANCE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 362. FRANCE GENETIC TESTIN

[183 Pages Report] The Genetic Testing Market size was estimated at USD 11.89 billion in 2023 and expected to reach USD 13.55 billion in 2024, at a CAGR 14.01% to reach USD 29.79 billion by 2030.

Genetic testing comprises a diverse range of products and services to analyze an individual's DNA to identify specific genes, chromosomes, or proteins linked to inherited traits, disease predispositions, or therapeutic responses. Various sectors, including clinical diagnostics, pharmaceutical research and development, biotechnology innovation, forensics, nutrigenomics, and direct-to-consumer services, are important business sectors in this market. Several factors have contributed to the significant growth of the genetic testing market in recent years. These include advancements in DNA sequencing technologies such as next-generation sequencing (NGS), increased awareness about early diagnosis benefits through genetic testing, growing prevalence of genetic disorders, an aging population, rising demand for personalized medicine, expanding use of direct-to-consumer genetic testing services, and supportive government policies coupled with favorable reimbursement scenarios. Emerging opportunities within the genetic testing market involve integrating with other cutting-edge technologies such as artificial intelligence (AI), big data analytics, and telemedicine platforms; entering high-growth markets such as Asia-Pacific; fostering public-private partnerships to bolster genomic research initiatives; applying precision medicine programs tailored to individual genetic profiles; and using liquid biopsy technology for early cancer detection via circulating tumor DNA (ctDNA) in blood samples. Nevertheless, the growth potential is hampered by several limitations and challenges that include ethical concerns regarding privacy issues and misuse of genetic information; insufficient public awareness about genetic testing's significance; affordability constraints due to high costs of advanced tests for certain segments of the population; inconsistent guidelines and regulations across countries; concerns over false results leading to misinterpretation by healthcare professionals and patients alike; and workforce shortage in areas such as certified genetic counselors.

Innovation and research efforts in the genetic testing market should be geared towards developing novel gene-editing technologies such as CRISPR-Cas9 for precision editing capabilities, enhancing bioinformatics tools for better interpretation of vast genomic data generated by high-throughput sequencing platforms, exploring new applications in non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA); discovering unique biomarkers for disease conditions that can be targeted through pharmacogenomics approaches; and expanding into fields such as environmental genomics to assess individual responses to various environmental factors.

Product: Penetration of software and services for efficient data management and analysis

Consumables and equipment in the genetic testing industry include products including reagents, assay kits, lab instruments, and devices required for sample collection, processing, and analysis. This segment is indispensable for performing accurate and reliable tests across various applications. Diagnostic Laboratories require high-quality consumables including reagents and assay kits for accurate diagnosis of diseases. In addition, research institutes rely on advanced equipment including sequencers or PCR machines to study genetics at a molecular level. On the other hand, the software and services includes bioinformatics tools for data storage, management, and analysis, as well as genetic counseling and consulting services. Software and services emphasizes data management and analysis solutions that cater to the growing need for efficient handling of complex genomic data.

Test Type: Emphasis on diagnostic testing to perform particular disease dignosis

Carrier testing is conducted to identify individuals with one copy of a gene mutation responsible for a genetic disorder in their offspring when paired with another carrier. It is often recommended for couples planning to have children, especially when there is a family history of specific genetic conditions. On the other hand, diagnostic testing is performed after an individual develops disease symptoms or needs to confirm or rule out a particular diagnosis. Newborn screening tests help identify potentially life-threatening infections in newborns as early as possible to initiate prompt medical intervention. The tests usually involve blood samples taken shortly after birth and may also include hearing screenings and pulse oximetry tests for congenital heart defects. Pharmacogenomics studies show how an individual's genetic makeup affects their medication response. By understanding these differences, healthcare professionals can optimize drug therapy selection and dosing for improved treatment outcomes. Preimplantation genetic testing is performed on embryos created through in vitro fertilization (IVF) to identify congenital abnormalities before uterine implantation. The two primary types of preimplantation testing are preimplantation genetic diagnosis (PGD), which screens for specific genetic disorders, and preimplantation genetic screening (PGS), which assesses embryo chromosomal makeup. Prenatal testing helps detect potential health problems during pregnancy and includes diagnostic tests (e.g., amniocentesis) and screenings (e.g., non-invasive prenatal testing or NIPT). Presymptomatic and predictive testing identifies genetic mutations in asymptomatic individuals who may be at high risk for developing specific diseases later in life. This testing information allows individuals to make informed decisions about their health management strategies or take preventive measures to reduce disease risk.

Technology: Increasing shift toward DNA sequencing for precise gene identification and disease diagnosis

Cytogenetics is the study of chromosomal abnormalities and their role in genetic disorders. Cytogenetics technology involves analyzing the structure and number of chromosomes and identifying aberrations that may contribute to disease development. Common cytogenetic tests include karyotyping and fluorescence in situ hybridization (FISH). DNA sequencing technology decodes the precise order of nucleotides within DNA molecules to identify genes and determine their function. The need-based preference for this technology lies in its ability to diagnose hereditary conditions, detect genetic mutations in cancer cells, and guide personalized medicine approaches. Gene expression profiling measures the activity levels of thousands of genes simultaneously to understand their role in disease development or progression. Gene expression profiling technology is useful for identifying novel therapeutic targets, understanding treatment responses, and guiding personalized therapy decisions. Microarrays and RNA sequencing (RNA-seq) are commonly used techniques for gene expression profiling. Microarrays are high-throughput technology platforms that analyze gene expression or detect genetic variations such as single nucleotide polymorphisms (SNPs). Their need-based preference includes studying gene function at the genome level or screening for potential disease-related biomarkers. PCR is a widely utilized molecular biology technique for amplifying and quantifying specific DNA sequences. PCR has various applications, including genetic testing, pathogen detection, and forensic analysis. The need-based preference for PCR is its ability to generate results quickly and accurately with minimal sample material.

Application: Rising adoption of genetic testing to detect early signs of cancer

Autoimmune disorders result from an immune system dysfunction, leading it to attack the body's cells and tissues. Genetic testing is crucial in identifying genetic predispositions for these conditions, enabling early detection and targeted treatment plans. A comprehensive understanding of an individual's genetic makeup can help detect early signs of cancer or identify familial risks, allowing for personalized prevention strategies and targeted therapies. Heart disease, diabetes, and obesity have complex interplays between environmental factors and genetics. Genetic testing assists in determining an individual's susceptibility to these conditions and helps develop tailored lifestyle interventions or medication plans to reduce risks. Cystic fibrosis, muscular dystrophy, and thalassemia are caused by mutations in specific genes. Genetic testing enables accurate diagnosis of genetic disorders and allows carrier screening to identify at-risk couples planning to have children. Neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's, can have strong genetic links. Genetic testing helps uncover predispositions to these conditions, enabling preventive measures or early interventions to slow disease progression.

Distribution Channel: Deployment of genetic testing products on online platforms

Offline distribution includes traditional brick-and-mortar establishments such as hospitals, clinics, and diagnostic laboratories, catering to individuals seeking personalized guidance through face-to-face interactions with healthcare professionals. The main benefits of offline distribution are direct consultation with medical experts, secure sample collection protocols, comprehensive insurance coverage options, and immediate access to follow-up care if needed. Online distribution represents a rapidly growing segment in the genetic testing market that appeals to tech-savvy individuals seeking convenient access to services from home. Major direct-to-consumer (DTC) brands predominantly offer ancestry or health-related tests through websites or eCommerce platforms. Advantages of online genetic testing include ease of use (sample collection kits mailed directly to users), quick turnaround times, cost-effectiveness, and access to a wide range of tests. However, it may lack personalized medical support available through offline channels. Ultimately, the choice between offline and online distribution depends on individual preferences and needs.

End-User: Extensive use of genetic testing solutions in hospitals & clinics for disease diagnosis and treatment planning

Diagnostic laboratories play a pivotal role in genetic testing due to their specialized services and extensive range of tests. Home-setting genetic testing is gaining popularity owing to the growing demand for direct-to-consumer (DTC) tests that provide insights into ancestry, health risks, and personal traits. Hospitals and clinics form another essential part of the end-user landscape as they integrate genetic testing services into patient care pathways for disease diagnosis and treatment planning. Hospitals have started incorporating pharmacogenomic testing to help tailor medication selection based on the patient's genetic makeup.

Regional Insights

The advanced healthcare infrastructure and strong government support for research and development in the Americas have led to a thriving genetic testing market. However, regulatory challenges remain as manufacturers must adhere to strict guidelines set by agencies such as the Food Drug Administration (FDA). Europe presents a diverse landscape with varying regulations across its member countries. The UK's Brexit has caused uncertainty in its regulatory framework. Manufacturers or providers must tailor their strategies to each country's specific requirements. The Middle East & Africa have potential for genetic testing providers due to growing populations and the increasing prevalence of chronic diseases. However, limited healthcare infrastructure and a lack of awareness about genetic testing services create challenges for entry into these markets. The APAC region offers major growth opportunities within China, Japan, and India as their large patient populations require accurate diagnosis and proactive management of hereditary conditions. Despite regulatory hurdles similar to those in developed countries, there is room for innovation catering to local context needs. Genetic testing is becoming vital to personalized medicine and preventive healthcare in developed countries; however, navigating complex regulations is crucial. In emerging countries, where potential lies for market expansion investment in local partnerships, educational initiatives, and infrastructure development. Recent news highlights collaborations aimed at improving offerings within the genetic testing market. Global genetic testing offers numerous opportunities to stay informed about regional trends and adapt strategies accordingly, ultimately contributing meaningfully to public health outcomes worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Blueprint Genetics Oy, Centogene N.V., Color Health, Inc., CooperSurgical Inc., Editas Medicine, Inc., ELITechGroup SAS, Eugene Labs Pty Ltd., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Fulgent Genetics, Inc., Gene by Gene, Ltd., GeneDx, LLC, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Living DNA Ltd., Macrogen, Inc., MyHeritage Ltd., Myriad Genetics, Inc., Natera, Inc., Newtopia Inc., PathogenDx Corporation, PerkinElmer Inc., Qiagen N.V., Sanofi S.A., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Consumables & Equipment
  • Software & Services

• Test Type
  • Carrier Testing
  • Diagnostic Testing
  • New Born Screening
  • Pharmacogenomics
  • Preimplantation Testing
  • Prenatal Testing
  • Presymptomatic & Predictive Testing

• Technology
  • Cytogenetics
  • DNA Sequencing
  • Gene Expression Profiling
  • Microarrays
  • PCR

• Application
  • Autoimmune Disorders
  • Cancer
  • Chronic Diseases
  • Genetic Disorders
  • Neurodegenerative Diseases

• Distribution Channel
  • Offline
  • Online

• End-User
  • Diagnostic Laboratories
  • Home Setting
  • Hospitals & Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Genetic Testing Market?

4. What is the market share of the leading vendors in the Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Genetic Testing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of genetic and oncology disorders and need for precision medicine
    • 5.1.1.2. Government initiatives for genetic testing and rise of self-test kits
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with false positives & negatives of genetic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and new developments in genetic testing technologies
    • 5.1.3.2. Emergence of genetic testing with telehealth and digital health platforms
  • 5.1.4. Challenges
    • 5.1.4.1. Logistical barriers and privacy concerns to genetic testing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Penetration of software and services for efficient data management and analysis
  • 5.2.2. Test Type: Emphasis on diagnostic testing to perform particular disease dignosis
  • 5.2.3. Technology: Increasing shift toward DNA sequencing for precise gene identification and disease diagnosis
  • 5.2.4. Application: Rising adoption of genetic testing to detect early signs of cancer
  • 5.2.5. Distribution Channel: Deployment of genetic testing products on online platforms
  • 5.2.6. End-User: Extensive use of genetic testing solutions in hospitals & clinics for disease diagnosis and treatment planning
• 5.3. Market Trend Analysis
  • 5.3.1. Technological advances and presence of established pharmaceutical companies enhance the genetic testing market growth in the Americas
  • 5.3.2. Increasing chronic disorders and expanding healthcare infrastructure supports genetic testing in the APAC region.
  • 5.3.3. Government initiatives and increasing demand for personalized medicine expand genetic testing market growth in the EMEA region.
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Genetic Testing Market, by Product

• 6.1. Introduction
• 6.2. Consumables & Equipment
• 6.3. Software & Services

7. Genetic Testing Market, by Test Type

• 7.1. Introduction
• 7.2. Carrier Testing
• 7.3. Diagnostic Testing
• 7.4. New Born Screening
• 7.5. Pharmacogenomics
• 7.6. Preimplantation Testing
• 7.7. Prenatal Testing
• 7.8. Presymptomatic & Predictive Testing

8. Genetic Testing Market, by Technology

• 8.1. Introduction
• 8.2. Cytogenetics
• 8.3. DNA Sequencing
• 8.4. Gene Expression Profiling
• 8.5. Microarrays
• 8.6. PCR

9. Genetic Testing Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Disorders
• 9.3. Cancer
• 9.4. Chronic Diseases
• 9.5. Genetic Disorders
• 9.6. Neurodegenerative Diseases

10. Genetic Testing Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Offline
• 10.3. Online

11. Genetic Testing Market, by End-User

• 11.1. Introduction
• 11.2. Diagnostic Laboratories
• 11.3. Home Setting
• 11.4. Hospitals & Clinics

12. Americas Genetic Testing Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Genetic Testing Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Genetic Testing Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. DNA company Asa Ren raises USD 8M and more briefs
  • 15.3.2. Devyser launches two new genetic testing solutions for hereditary cancer
  • 15.3.3. Blueprint Genetics introduces the new Screening Tests family; giving actionable insights for family planning, and future health
  • 15.3.4. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
  • 15.3.5. Genetic Testing Firm Delve Gets USD 35 Million in VC Funding
  • 15.3.6. FBI approves QIAGEN's NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
  • 15.3.7. Sema4 to acquire genetic testing firm GeneDx for USD 623 Million
  • 15.3.8. Scribe and Sanofi expand genetic therapy development deal
  • 15.3.9. healthOme Acquires Kailos Genetics
  • 15.3.10. MapMyGenome launches India's First DNA Test For Personalized Skin And Hair Care
  • 15.3.11. CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
  • 15.3.12. PathogenDx Expands Reach of Its Patented Multiplexed Molecular Testing Technology, Bringing It to the Clinical, Food and Agriculture Sectors
  • 15.3.13. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
  • 15.3.14. Invitae Announces Partnership with Epic to Streamline Genetic Testing
  • 15.3.15. Grand Launching Of DNATEST.ID, A Comprehensive Dna Test In Indonesia
  • 15.3.16. MyHeritage Releases cM Explainer to Predict Familial Relationships Between DNA Matches with Greater Accuracy

16. Competitive Portfolio

• 16.1. Key Company Profiles
• 16.2. Key Product Portfolio